Stockscreener 앱 받기
20.52
1.39%
-0.29
시간 외 거래:
21.22
0.70
+3.41%
Syndax Pharmaceuticals Inc 주식(SNDX)의 최신 뉴스
Syndax Pharmaceuticals Inc (SNDX) Cash Flow - TradingKey
Syndax Pharmaceuticals Inc (SNDX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Syndax Pharmaceuticals (SNDX) Projected to Announce Quarterly Earnings on Monday - MarketBeat
Orbimed Advisors LLC Invests $22.48 Million in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
SNDX|Syndax Pharmaceuticals Inc|Price:20.810|Chg%:-0.400 - TradingKey
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Syndax Pharmaceuticals Inc (SNDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Granahan Investment Management LLC Cuts Stock Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Price to sales forward of Syndax Pharmaceuticals Inc – SWB:1T3 - TradingView
Syndax Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:SNDX - TradingView
Syndax Pharmaceuticals Inc. (SNDX) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Technical Reactions to SNDX Trends in Macro Strategies - Stock Traders Daily
Barclays Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $37 - Moomoo
Syndax Pharmaceuticals (SNDX) Receives a New Rating from a Top Analyst - The Globe and Mail
Syndax Pharmaceuticals (SNDX) FDA Announcement Summary - Quartr
Syndax Pharmaceuticals (SNDX) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Syndax Pharmaceuticals Inc. (SNDX) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Syndax Pharmaceuticals (SNDX) Is Up 8.20% in One Week: What You Should Know - Yahoo! Finance Canada
Syndax Pharmaceuticals (SNDX) Could Be 40% Undervalued As Pipeline Updates Sharpen Growth Story - Sahm
SNDX Stock Price, Quote & Chart - ChartMill
Goldman Sachs Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Analysts Have Conflicting Sentiments on These Healthcare Companies: HCA Healthcare (HCA) and Syndax Pharmaceuticals (SNDX) - The Globe and Mail
TD Cowen Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating - Moomoo
SNDX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Stifel Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $46 - Moomoo
Syndax Pharmaceuticals unveils new pipeline candidates - BioWorld News
Syndax Pharmaceuticals (NASDAQ:SNDX) Earns "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright reiterates Syndax Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Citi Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $57 - Moomoo
Syndax Showcases Late-Stage Pipeline, Expands R&D Strategy - TipRanks
SNDX6417984 Bond Coupon Profile — Rate & Payments - TradingView
Syndax Pharmaceuticals Inc to Host R&D Day Transcript - GuruFocus
SNDX6417984 Bond Profile — Key Metrics - TradingView
A Fresh Look At Syndax Pharmaceuticals (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push - MarketBeat
Syndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Lead TherapiesSlideshow (NASDAQ:SNDX) 2026-07-14 - Seeking Alpha
Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet - Yahoo! Finance Canada
SNDX: New pipeline assets and late-stage programs drive clinical and commercial growth through 2027 - TradingView
Syndax (NASDAQ: SNDX) details pipeline expansion and 2026-27 clinical catalysts - Stock Titan
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event - The Manila Times
Form 4 Syndax Pharmaceuticals For: 9 July By Investing.com - Investing.com Nigeria
Syndax CEO Michael Metzger sells $784,776 in company stock By Investing.com - Investing.com Nigeria
Syndax CEO Michael Metzger sells $784,776 in company stock - Investing.com
Syndax Pharmaceuticals Insider Sold Shares Worth $784,776, According to a Recent SEC Filing - Moomoo
Syndax (SNDX) CEO Metzger exercises options and sells 32,375 shares under 10b5-1 plan - Stock Titan
Syndax Pharmaceuticals (NASDAQ:SNDX) CEO Sells 32,375 Shares - MarketBeat
Syndax Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Metzger Michael A - Moomoo
Form 144 Syndax Pharmaceuticals For: 8 July By Investing.com - Investing.com Nigeria
SNDX insider files to sell 32,375 shares (NASDAQ: SNDX) - Stock Titan
Syndax Pharmaceuticals (SNDX) TD Cowen 45th Annual Healthcare Conference Summary - Quartr
Why Syndax Pharmaceuticals (SNDX) Is Up 6.3% After Broad Russell Value Index Removal And What's Next - simplywall.st
Syndax Pharmaceuticals holds steady as investors await a fresh catalyst - ad-hoc-news.de
SG Americas Securities LLC Has $900,000 Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
1.97%
0.83%
자본화:
|
볼륨(24시간):